In vitro and in vivo studies of AT-1362, a newly synthesized and orally active inhibitor of thrombin

Thrombosis Research

Volumn 100, Issue 1, 2000, Pages 97-107

  Cho, Jae hyung ^a   Seo, Hyoung sik ^a   Yun, Chi ho ^a   Koo, Bon am ^a   Yoshida, Shoshin ^b   Koga, Takaki ^b   Dan, Takashi ^b   Kim, Hak yeop ^a,c  

^a C and C Research Laboratories   (South Korea)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^c C Research Laboratories   (South Korea)

Author keywords

Antithrombotic effects; Argatroban; AT 1362; Bleeding time; Clotting time

Indexed keywords

ARGATROBAN; AT 1362; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; CAROTID ARTERY THROMBOSIS; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOGENESIS; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; AMIDINES; ANIMAL; BINDING, COMPETITIVE; BLEEDING TIME; COMPARATIVE STUDY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FERROUS COMPOUNDS; FIBRINOLYTIC AGENTS; HUMAN; MALE; MOLECULAR STRUCTURE; PARTIAL THROMBOPLASTIN TIME; PIPECOLIC ACIDS; PROTEIN BINDING; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; THROMBIN; VASCULAR PATENCY; VENOUS THROMBOSIS;

EID: 0034306572     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00298-X     Document Type: Article

References (36)

1. New antithrombotic drugs: A perspective
2. New anticoagulant strategies. Current status and future potential
3. Development of argatroban, a direct thrombin inhibitor, and its clinical application
4. Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl )-sulfonyl]-L-arginyl]-2-piperi-dinecarboxylic acid
5. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: Comparison with heparin and recombinant hirudin
6. Modulating platelet function with selective thrombin inhibitors
7. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time
8. Antithrombotic activity of argatroban in experimental thrombosis in the rabbit
9. Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: Comparison with heparin
10. Low-molecular-weight heparin (Fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time
11. A multi-center, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: Myocardial infarction with novastan and TPA (MINT) study
12. A randomized blinded study of two doses of Novastan(R) (brand of argatroban) versus heparin as adjunctive therapy to recombinant tissue plasminogen activator (accelerated administration) in acute myocardial infarction: Rationale and design of the myocardial infarction using Novastan(R) and t-PA (MINT) Study
13. Determination of theophylline in plasma ultrafiltrate by reversed phase high pressure liquid chromatography
14. A new experimental model of venous thrombosis in rats involving partial stasis and slight endothelium alterations
15. Rat model of arterial thrombosis induced by ferric chloride
16. The use of dihydroergotamine and heparin in the prophylaxis of deep venous thrombosis
17. Pathogenesis of venous thrombosis: A new insight
18. Rat jugular vein hemostasis - A new model for testing antithrombotic agents
19. Comparative study on the effects of a low molecular weight heparin (CY216) and standard heparin in low dosage on experimental venous thrombosis
20. Prevention of experimental venous thrombosis in rabbits with low molecular weight heparin, dextran and their combinations, administered before or during induction of venous endothelial trauma
21. A novel model of venous thrombosis in the vena cava of rabbits
22. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat
23. Pharmacokinetic studies of argipidine (MD-805) - Protein binding and blood cell binding
24. Prevention and treatment of venous thromboembolism
25. Pharmaco-kinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT
26. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis
27. An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis
28. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental thrombosis
29. Ecarin clotting time: A predictive coagulation assay for the antithrombotic activity of argatroban in the rat
30. Coagulation laborotory testing in patients treated with argatroban
31. Factor XI and protection of the fibrin clot against lysis - A role for the intrinsic pathway of coagulation in fibrinolysis
32. Pathology of arterial thrombosis
33. Effect of thrombin inhibitors on platelet functions: Comparative analysis of DuP714 and hirudin
34. Characterization of in vitro and in vivo platelet responses to thrombin and thrombin receptor-activating peptides in guinea pigs
35. Guide to anticoagulant therapy Part 2: Oral Anticoagulants